公开(公告)号：WO2011154418A1

公开(公告)日：2011-12-15

申请号：PCT/EP2011/059417

申请日：2011-06-07

申请人： FARMA-DERMA SRL ,  RUSSO, Vincenzo

发明人： RUSSO, Vincenzo

IPC分类号： A61K9/00 ,  A61K9/02 ,  A61K9/16 ,  A61K31/728 ,  A61K47/36 ,  A61K47/44 ,  A61K36/00

CPC分类号： A61K9/0031 ,  A61K9/0034 ,  A61K9/02 ,  A61K9/1688 ,  A61K31/728 ,  A61K36/23 ,  A61K36/28 ,  A61K36/886 ,  A61K47/36 ,  A61K47/44 ,  A61K2300/00

摘要： A preparation for vaginal and rectal use comprising hyaluronic acid, with an average particle size comprised between about 50 micrometers and about 200 micrometers and a molecular weight comprised between about 1,000,000 Da and about 1,800,000 Da.

摘要翻译： 一种用于阴道和直肠用途的制剂，其包含透明质酸，平均粒径为约50微米至约200微米，分子量为约1,000,000Da至约1,800,000Da。

公开(公告)号：WO2010084038A1

公开(公告)日：2010-07-29

申请号：PCT/EP2010/050137

申请日：2010-01-08

申请人： AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. ,  SELVA, Stefano ,  MARCHITTO, Leonardo ,  CIOTTOLI, Giovanni Battista ,  RAGNI, Lorella ,  RUSSO, Vincenzo ,  LIBERATI, Elisa

发明人： SELVA, Stefano ,  MARCHITTO, Leonardo ,  CIOTTOLI, Giovanni Battista ,  RAGNI, Lorella ,  RUSSO, Vincenzo ,  LIBERATI, Elisa

IPC分类号： A61K9/20

CPC分类号： A61K9/205 ,  A61K9/2054

摘要： The present invention relates to a controlled release pharmaceutical or food formulation comprising at least one active pharmaceutical or food ingredient dispersed in a mixture of a glycogen with a polysaccharide, and the process for its preparation. The invention also relates to a slow release system represented by a mixture of a glycogen with a polysaccharide, and its use for the preparation of slow release pharmaceutical or food formulations.

摘要翻译： 本发明涉及包含分散在糖原与多糖的混合物中的至少一种活性药物或食品成分的控释药物或食品制剂及其制备方法。 本发明还涉及由糖原与多糖的混合物表示的缓释系统及其用于制备缓释药物或食品制剂的用途。

公开(公告)号：WO2011077245A3

公开(公告)日：2012-04-12

申请号：PCT/IB2010003447

申请日：2010-12-23

申请人： SAN RAFFAELE CENTRO FOND ,  RUSSO VINCENZO ,  TRAVERSARI CATIA

发明人： RUSSO VINCENZO ,  TRAVERSARI CATIA

IPC分类号： A61K45/06 ,  A61K31/357 ,  A61K31/381 ,  A61K31/404 ,  A61K31/4178 ,  A61K31/4196 ,  A61K31/4433 ,  A61K31/496 ,  A61K31/575 ,  A61K39/395 ,  A61P35/00

CPC分类号： A61K31/4433 ,  A61K31/357 ,  A61K31/381 ,  A61K31/404 ,  A61K31/4178 ,  A61K31/4196 ,  A61K31/496 ,  A61K31/575 ,  A61K39/395 ,  A61K2300/00

摘要： The invention relates to the discovery that human and murine tumors release LXR ligands (oxysterols) that inhibit CCR7 expression on maturing DC and, therefore, their migration to lymphoid organs. By inhibiting oxysterol synthesis (by Zaragozic Acid, ZA) or by inactivating oxysterols (gene therapy with sulfotransferase SULT2B1 b enzyme) long lasting antigen specific anti-tumor immune response mediated by DC is increased. Surprisingly, we also show that drugs interfering with sterol metabolism (i.e. ZA) in combination with a mAb depleting T regulatory cells potentiate the antitumor effect of the single treatments. This synergic effect is unexpected, providing a new effective combination therapy for the treatment of cancer. The invention also relates to the novel use of LXR ligand inactivators, or of LXR inhibitors/antagonists, for the treatment of cancer. These strategies can also be used in combination with a chemotherapy approach for the treatment of cancer patients.

摘要翻译： 本发明涉及人和鼠肿瘤释放在成熟DC上抑制CCR7表达并因此其向淋巴器官迁移的LXR配体（氧固醇）的发现。 通过抑制氧固醇合成（通过Zaragozic Acid，ZA）或通过使氧固醇失活（用磺基转移酶SULT2B1b酶进行基因治疗），由DC介导的持久抗原特异性抗肿瘤免疫应答增加。 令人惊讶的是，我们还表明，干扰固醇代谢（即ZA）与消耗血清单克隆抗体T调节细胞的组合的药物增强了单次治疗的抗肿瘤作用。 这种协同效应是意想不到的，为治疗癌症提供了一种新的有效的联合疗法。 本发明还涉及LXR配体灭活剂或LXR抑制剂/拮抗剂在治疗癌症中的新用途。 这些策略也可以与化疗方案结合使用，用于治疗癌症患者。

公开(公告)号：WO2011015509A1

公开(公告)日：2011-02-10

申请号：PCT/EP2010/061002

申请日：2010-07-29

申请人： AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. ,  RUSSO, Vincenzo ,  LIBERATI, Elisa ,  BIONDI, Giuseppe

发明人： RUSSO, Vincenzo ,  LIBERATI, Elisa ,  BIONDI, Giuseppe

IPC分类号： A23L1/056 ,  A23L1/30 ,  A61K31/715 ,  A61K35/56

CPC分类号： A23L1/30 ,  A23L33/10 ,  A23V2002/00 ,  A23V2200/30 ,  A23V2250/51 ,  A23V2250/2042 ,  A23V2250/204 ,  A23V2250/208

摘要： The present invention relates to a food formulation for the controlled release of glucose comprising glycogen and at least one other edible component, as well the use of glycogen for its preparation.

摘要翻译： 本发明涉及用于控制葡萄糖释放的食物制剂，其包含糖原和至少一种其它可食用成分，以及糖原用于其制备。

公开(公告)号：WO2006120653A3

公开(公告)日：2007-04-05

申请号：PCT/IB2006051516

申请日：2006-05-15

申请人： BIOLAB S P A ,  UNIV BOLOGNA ALMA MATER ,  PANCALDI MARCO ,  FONTANESI LUCA ,  SALVI ALESSANDRO ,  RUSSO VINCENZO ,  DAVOLI ROBERTA ,  CARBONI ELENA

发明人： PANCALDI MARCO ,  FONTANESI LUCA ,  SALVI ALESSANDRO ,  RUSSO VINCENZO ,  DAVOLI ROBERTA ,  CARBONI ELENA

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6888 ,  C12Q1/689 ,  C12Q1/6893 ,  C12Q1/6895 ,  C12Q2600/156

摘要： The present invention relates tracers for foods comprising natural nucleotide sequences, methods for the production thereof, uses of said tracers and food products labelled with said tracers.

摘要翻译： 本发明涉及包含天然核苷酸序列的食品的追踪剂，其生产方法，所述示踪剂的用途和用所述示踪剂标记的食品。

公开(公告)号：WO2007014687A1

公开(公告)日：2007-02-08

申请号：PCT/EP2006/007393

申请日：2006-07-25

申请人： AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. ,  ALISI, Maria, Alessandra ,  DRAGONE, Patrizia ,  FURLOTTI, Guido ,  CAZZOLLA, Nicola ,  RUSSO, Vincenzo ,  MANGANO, Giorgina ,  COLETTA, Isabella ,  POLENZANI, Lorenzo

发明人： ALISI, Maria, Alessandra ,  DRAGONE, Patrizia ,  FURLOTTI, Guido ,  CAZZOLLA, Nicola ,  RUSSO, Vincenzo ,  MANGANO, Giorgina ,  COLETTA, Isabella ,  POLENZANI, Lorenzo

IPC分类号： C07D209/88 ,  A61K31/403 ,  A61P35/00

CPC分类号： C07D209/88

摘要： A compound of formula (I), in which R1 , R2, R3, R4, R5, R6, X and Y have the meanings indicated in the description, and the pharmaceutically acceptable salts thereof. A pharmaceutical composition containing a compound of formula (I) or a pharmaceutically acceptable salt thereof. A method for preparing the abovementioned compound of formula (I) and the pharmaceutically acceptable salts thereof.

摘要翻译： 其中R1，R2，R3，R4，R5，R6，X和Y具有说明书中所示含义的式（I）化合物及其药学上可接受的盐。 含有式（I）化合物或其药学上可接受的盐的药物组合物。 一种制备上述式（I）化合物及其可药用盐的方法。

公开(公告)号：WO2005123034A8

公开(公告)日：2006-03-30

申请号：PCT/IT2005000353

申请日：2005-06-20

申请人： UNIV DEGLI STUDI MILANO ,  UNIV PAVIA ,  VIGO DANIELE ,  RUSSO VINCENZO ,  FAUSTINI MASSIMO ,  PACE MARIO FRANCESCO ,  MUNARI ELEONORA ,  TORRE MARIA LUISA ,  CONTE UBALDO

发明人： VIGO DANIELE ,  RUSSO VINCENZO ,  FAUSTINI MASSIMO ,  PACE MARIO FRANCESCO ,  MUNARI ELEONORA ,  TORRE MARIA LUISA ,  CONTE UBALDO

IPC分类号： A61K9/00 ,  A61K9/16

CPC分类号： A61K9/1652 ,  A61K9/1623 ,  A61K9/1635 ,  A61K9/1694

摘要： The present invention relates to microparticulate systems consisting of a gastroresistant, biocompatible and biodegradable polymer matrix, comprising a gastroresistant and enterosoluble polymer, a cryoprotector or lyoprotector, a divalent or trivalent metal salt of i biocompatible and biodegradable polymer having acid groups, and biologically active substances. Such gastroresistant microparticulate systems are used for the administration, preferably oral, of biologically active substances to animal species. The special composition of such microparticulate systems allows the protection of said biologically active substances from degradation by proteases and gastric acid, allowing their release into the intestine, where they may perform their activities.

摘要翻译： 本发明涉及由耐胃液，生物相容性和可生物降解的聚合物基质组成的微粒系统，其包含胃耐受性和肠溶性聚合物，低温保护剂或冻干保护剂，具有酸基的生物相容且可生物降解的聚合物的二价或三价金属盐和生物活性物质 。 这种耐胃液微粒系统用于给予动物物种的生物活性物质，优选口服给药。 这种微粒体系的特殊组成允许保护所述生物活性物质免受蛋白酶和胃酸降解，允许它们释放到肠中，在那里它们可以进行它们的活动。

公开(公告)号：WO2005041942A9

公开(公告)日：2005-07-28

申请号：PCT/EP2004012384

申请日：2004-11-02

申请人： UNIV DEGLI STUDI MILANO ,  UNIV PAVIA ,  UNIV BOLOGNA ,  VIGO DANIELE ,  RUSSO VINCENZO ,  FAUSTINI MASSIMO ,  STACCHEZZINI SIMONA ,  CONTE UBALDO ,  TORRE MARIA LUISA ,  ACCORSI PIER ATTILIO ,  GALEATI GIOVANNA ,  SPINACI MARCELLA

发明人： VIGO DANIELE ,  RUSSO VINCENZO ,  FAUSTINI MASSIMO ,  STACCHEZZINI SIMONA ,  CONTE UBALDO ,  TORRE MARIA LUISA ,  ACCORSI PIER ATTILIO ,  GALEATI GIOVANNA ,  SPINACI MARCELLA

IPC分类号： A61K9/16 ,  A61K9/50 ,  A61K35/48 ,  C12N5/00 ,  C12N5/075 ,  C12N11/00 ,  C12N5/08

CPC分类号： C12N5/0609 ,  A61K9/5036 ,  A61K35/48 ,  C12N5/0012 ,  C12N2502/243 ,  C12N2533/74

摘要： A process for encapsulating and immobilising mammalian stem cells, ovarian follicular cells, gametes, ovarian follicles or mammalian embryos which are able to auto-organise into three-dimensional structures in vitro, and express biological functions in a manner similar to that which is observed in the organism in vivo is described. The capsules are constituted by: a nucleus containing stem cells, ovarian follicular cells, gametes, ovarian follicles or mammalian embryos and/or a biocompatible and/or biodegradable polymer; a semi-permeable membrane constituted by a divalent or trivalent metal ion salt of alginic acid, optionally cross-linked on the inner and/or outer surface and/or on both surfaces, optionally vehicularising a second or more cellular species. The cells and follicles prepared and cultivated using this methodology are used for the in vitro and/or in vivo production of peptides, proteins, antibodies, hormones and hormone precursors, metabolites and catabolites typical of these cellular structures, plasma membranes, nuclear membranes, cytoplasmic organelles, somatic cell nuclei or gametes and embryos.

摘要翻译： 一种封装和固定能够在体外自动组织成三维结构的哺乳动物干细胞，卵泡滤泡细胞，配子，卵泡或哺乳动物胚胎的方法，并以类似于 描述体内生物体。 胶囊由以下组成：含有干细胞，卵泡滤泡细胞，配子，卵泡或哺乳动物胚胎和/或生物相容性和/或可生物降解的聚合物的细胞核; 由藻酸的二价或三价金属离子盐构成的半透膜，任选地在内表面和/或外表面上和/或两个表面上交联，任选地驱动第二种或更多种细胞物质。 使用该方法制备和培养的细胞和滤泡用于体外和/或体内产生肽，蛋白质，抗体，激素和激素前体，这些细胞结构，质膜，核膜，细胞质的典型代谢物和分解代谢物 细胞器，体细胞核或配子和胚胎。

公开(公告)号：WO2011077245A2

公开(公告)日：2011-06-30

申请号：PCT/IB2010/003447

申请日：2010-12-23

申请人： FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR ,  RUSSO, Vincenzo ,  TRAVERSARI, Catia

发明人： RUSSO, Vincenzo ,  TRAVERSARI, Catia

IPC分类号： A61K45/06

CPC分类号： A61K31/4433 ,  A61K31/357 ,  A61K31/381 ,  A61K31/404 ,  A61K31/4178 ,  A61K31/4196 ,  A61K31/496 ,  A61K31/575 ,  A61K39/395 ,  A61K2300/00

摘要： The invention relates to the discovery that human and murine tumors release LXR ligands (oxysterols) that inhibit CCR7 expression on maturing DC and, therefore, their migration to lymphoid organs. By inhibiting oxysterol synthesis (by Zaragozic Acid, ZA) or by inactivating oxysterols (gene therapy with sulfotransferase SULT2B1 b enzyme) long lasting antigen specific anti-tumor immune response mediated by DC is increased. Surprisingly, we also show that drugs interfering with sterol metabolism (i.e. ZA) in combination with a mAb depleting T regulatory cells potentiate the antitumor effect of the single treatments. This synergic effect is unexpected, providing a new effective combination therapy for the treatment of cancer. The invention also relates to the novel use of LXR ligand inactivators, or of LXR inhibitors/antagonists, for the treatment of cancer. These strategies can also be used in combination with a chemotherapy approach for the treatment of cancer patients.

摘要翻译： 本发明涉及人和鼠肿瘤释放在成熟DC上抑制CCR7表达并因此其向淋巴器官迁移的LXR配体（氧固醇）的发现。 通过抑制氧固醇合成（通过Zaragozic Acid，ZA）或通过使氧固醇失活（用磺基转移酶SULT2B1b酶进行基因治疗），由DC介导的持久抗原特异性抗肿瘤免疫应答增加。 令人惊讶的是，我们还表明，干扰固醇代谢（即ZA）与消耗血清单克隆抗体T调节细胞的组合的药物增强了单次治疗的抗肿瘤作用。 这种协同效应是意想不到的，为治疗癌症提供了一种新的有效的联合疗法。 本发明还涉及LXR配体灭活剂或LXR抑制剂/拮抗剂在治疗癌症中的新用途。 这些策略也可以与化疗方案结合使用，用于治疗癌症患者。

公开(公告)号：WO2009083561A1

公开(公告)日：2009-07-09

申请号：PCT/EP2008/068256

申请日：2008-12-23

申请人： AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. ,  RUSSO, Vincenzo ,  LIBERATI, Elisa ,  CAZZOLLA, Nicola ,  MARCHITTO, Leonardo ,  RAGNI, Lorella

发明人： RUSSO, Vincenzo ,  LIBERATI, Elisa ,  CAZZOLLA, Nicola ,  MARCHITTO, Leonardo ,  RAGNI, Lorella

IPC分类号： A61K31/00 ,  A61K9/20 ,  A61K9/16

CPC分类号： A61K9/2009 ,  A61K9/1611 ,  A61K9/1652 ,  A61K9/205 ,  A61K9/2059 ,  A61K31/00

摘要： The present invention relates to a controlled-release pharmaceutical formulation comprising at least one active ingredient dispersed in a matrix comprising at least one slow-release excipient comprising an association of at least one glycogen and at least one alginate with alkaline-earth metal salts, and a process for its preparation. The invention also relates to a slow-release excipient comprising an association of at least one glycogen and at least one alginate with alkaline-earth metal salts, and the process for its preparation, and its use for the preparation of slow-release pharmaceutical formulations.

摘要翻译： 本发明涉及包含分散在基质中的至少一种活性成分的控释药物制剂，其包含至少一种缓释赋形剂，其包含至少一种糖原和至少一种藻酸盐与碱土金属盐的缔合，以及 其准备过程。 本发明还涉及包含至少一种糖原和至少一种藻酸盐与碱土金属盐的缔合的缓释赋形剂及其制备方法及其用于制备缓释药物制剂的用途。